In the saxaglitpin SAVOR-TIMI 53 trial, 16,492 diabetic subjects with a history of myocardial infarction (MI), or documented atherosclerosis, or at least one of hypertension, smoking, or dyslipidemia and HbA1c 6.5–12% were randomized to receive saxagliptin or placebo, in addition to other diabetes medications (predominantly metformin, sulfonylurea and insulin) [79]. Here, INS is linked to myocardial infarction.